特发性门静脉高压症预后及其影响因素*

doi:10.3969/j.issn.1672-5069.2018.03.004

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (3): 332-335.doi: 10.3969/j.issn.1672-5069.2018.03.004

特发性门静脉高压症预后及其影响因素*

杨凯奇, 陈世耀

200032上海市复旦大学附属中山医院消化科

收稿日期:2018-03-16 出版日期:2018-05-10 发布日期:2018-05-25
通讯作者: 陈世耀, E-mail:chen.shiyao@zs-hospital.sh.cn
作者简介:杨凯奇,女,24岁,临床医学八年制博士研究生。主要从事消化病诊断与治疗学研究。E-mail:12301010066@fudan.edu.cn
基金资助:
*上海市科学技术委员会科技创新项目（编号：15411950501）

Prognosis of patients with idiopathic portal hypertension

Yang Kaiqi, Chen Shiyao

Department of Gastroenterology,Zhongshan Hospital,Fudan University,Shanghai 200032,China

Received:2018-03-16 Online:2018-05-10 Published:2018-05-25

摘要/Abstract

关键词: 特发性门静脉高压症, 预后, 并发症

Key words: Idiopathic portal hypertension, Prognosis, Complications

杨凯奇, 陈世耀. 特发性门静脉高压症预后及其影响因素*[J]. 实用肝脏病杂志, 2018, 21(3): 332-335.

Yang Kaiqi, Chen Shiyao. Prognosis of patients with idiopathic portal hypertension[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 332-335.

[1] Schouten JN,Garcia-Pagan JC,Valla DC,et al.Idiopathic noncirrhotic portal hypertension. Hepatology,2011,54(3): 1071-1081.
[2] Eapen CE,Nightingale P,Hubscher SG,et al.Non-cirrhotic intrahepatic portal hypertension:associated gut diseases and prognostic factors. Dig Dis Sci,2011,56(1):227-235.
[3] Hillaire S,Bonte E,Denninger MH,et al.Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut,2002,51(2):275-280.
[4] Cazals-Hatem D,Hillaire S,Rudler M,et al.Obliterative portal venopathy:portal hypertension is not always present at diagnosis. J Hepatol,2011,54(3):455-461.
[5] Okuda K.Non-cirrhotic portal hypertension:why is it so common in India. J Gastroenterol Hepatol,2002,17(1):1-5.
[6] Sarin SK,Kapoor D.Non-cirrhotic portal fibrosis:current concepts and management. J Gastroenterol Hepatol,2002,17(5): 526-534.
[7] Siramolpiwat S,Seijo S,Miquel R,et al.Idiopathic portal hypertension:natural history and long-term outcome. Hepatology,2014,59(6):2276-2285.
[8] Schouten JN,Nevens F,Hansen B,et al.Idiopathic noncirrhotic portal hypertension is associated with poor survival:results of a long-term cohort study. Aliment Pharmacol Ther,2012,35(12): 1424-1433.
[9] Maruyama H,Kondo T,Sekimoto T,et al.Differential clinical impact of ascites in cirrhosis and idiopathic portal hypertension. Medicine (Baltimore),2015,94(26):e1056.
[10] Fujiyama S,Saitoh S,Kawamura Y,et al.Portal vein thrombosis in liver cirrhosis:incidence,management,and outcome. BMC Gastroenterol,2017,17(1):112.
[11] Matsutani S,Maruyama H,Akiike T,et al.Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Liver Int,2005,25(5):978-983.
[12] Chang PE,Miquel R,Blanco JL,et al.Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol,2009,104(7):1707-1714.
[13] Orozco H,Guraieb E,Takahashi T,et al.Deficiency of protein C in patients with portal vein thrombosis. Hepatology,1988,8(5):1110-1111.
[14] Valla DC,Condat B.Portal vein thrombosis in adults:pathophysiology,pathogenesis and management. J Hepatol,2000,32(5):865-871.
[15] Hirohata Y,Murata A,Abe S,et al.Portal vein thrombosis associated with antiphospholipid syndrome. J Gastroenterol,2001,36(8):574-578.

特发性门静脉高压症预后及其影响因素*

Prognosis of patients with idiopathic portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[2]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[3]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[4]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[5]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[6]	祁莉娜, 颜梅, 郭建琴. 腹腔镜下肝囊肿开窗术与超声引导下穿刺介入治疗单纯性肝囊肿患者疗效对比研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 581-584.
[7]	卢西梅, 康燕飞, 宋智勇, 朱乔. 彩色多普勒超声检查诊断肝移植术后胆道并发症价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 589-592.
[8]	马信奎, 刘勇, 张伟. 经皮经肝胆道镜硬镜碎石术治疗肝内胆管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 593-596.
[9]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[10]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[11]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[12]	马德渊, 马元凤, 张殿隆, 李山林. HBV相关慢加急性肝衰竭患者血清角蛋白18水平及其与患者预后的关系探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 77-80.
[13]	马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 125-128.
[14]	于旭彤, 蒋秀华, 祁婷婷, 何钦俊, 周福元, 陈永鹏, 文维群, 陈金军. 前瞻性研究四种出血事件评估标准评估慢加急性肝衰竭患者出血事件^*[J]. 实用肝脏病杂志, 2018, 21(6): 885-889.
[15]	安宝燕, 王云, 项晓刚, 陈利文, 闫蕾, 曹竹君, 丁叶舟, 汤伟亮, 林兰意, 谢青, 王晖. 乙型肝炎相关性肝细胞癌患者预后的多因素分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 924-927.